Teva Pharma Industries Ltd (TEVA) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Teva Pharma Industries Ltd stock $20.82, price $42.09, that is 50.5% below the price, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
HealthcareUS · ADR · Home Israel · ISIN US8816242098
TPSome dataNov 1, 2026
Teva Pharma Industries Ltd
TEVA · US
Solid,but very expensive
Our calculation puts a fair price 51% below what the stock costs today.
Generates free cash flow
Quality 51/100
Thin margins · 4.1% net margin (TTM)
Some data
Costs 70 times its yearly profit.
Fair value $20.82 · Strongly overvalued (−50.5%)
Weak Growth(revenue 5y +0.7 %/yr in USD)
High debt
Trails peers(1/13)
Narrow moat35/100
Risks from the AI analysis
🚩Ongoing legal settlements drain cash🚩FTC and EU actions boost generic competition
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 1, 2026.
How to read this chart
60‑month range $6.86 – $42.09 · fair‑value band $10.71 – $31.83 · the $42.09 price screens above the $20.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 1, 2026.
Follow Teva Pharma Industries Ltd ADR in your weekly email
Every Wednesday you see whether Teva Pharma Industries Ltd ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally.
Show moreShow less
It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders " chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder.
The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names.
It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Stock analysis
Teva Pharma Industries Ltd (TEVA) currently trades at $42.09, while our model-based Fair Value estimate is $20.82, 50.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $24.48 per share, and 0 of the 22 models we run sit above the $42.09 price.
Bear case: the Earnings-Based group reads lowest at $9.65, and 22 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $10.71 (bear) to $31.83 (bull), the price of $42.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Teva Pharma Industries Ltd ADR reported revenue of $17.3B in FY2025 versus $15.9B in FY2021, a compound +2.1%/yr. Reported net income was $1.4B in FY2025, compounding +35.6%/yr from FY2021.
Key figures
Market cap $49.7B Large · P/E ratio 70.2 · P/S ratio 2.87 · EPS (TTM) $0.6000 · Net margin 4.1% · Return on equity 9.7% · Return on assets (EBIT) 0.8% · Operating margin 4.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 35 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades at its 52-week high and 110% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −51%, TEVA screens richer than that median.
Fair Value models
Bear$10.71Fair Value $20.82Bull$31.83
Price $42.09 · Downside -50.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.5030 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+4.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2020 (pandemic). Over 10 years: −1.3% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+26.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.26.1% vs −4.2%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−21% → 13%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 4.7%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+25.9%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+1.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +22.9% a year for the price and −0.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Generic drug scale delivers operational reach yet the limited durable moat amid heavy competition and modest returns on capital remains the core constraint.
Main risk: Scheduled payments for opioids and other settlements could continue to require hundreds of millions in annual cash outflows through 2029, limiting funds available for pipeline development or debt reduction.
Bull case: Teva could leverage its scale in generics and new CNS launches like Weltruza to offset legal cash outflows while navigating regulatory pressures through efficient patent strategies and partnerships.
Bear case: Persistent legal payments combined with accelerated generic competition from regulatory actions could constrain investment in innovative products and erode margins across core segments for years.
Teva just gained FDA approval for WELTRUZA, the first once-monthly subcutaneous olanzapine injection for schizophrenia that needs no loading doses or post-injection monitoring. Its established generics and biosimilars business still contends with pricing pressure and competition. Can the newer CNS products generate enough sustained contribution to reduce dependence on those core segments?
Compare Teva Pharma Industries Ltd ADR with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 550 stocks
Beats the industry median on 1/13 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−50.5% · Below median
Profitability
Return on equity (12 months)9.7% · Above median
Return on assets3.5% · Below median
Net margin (12 months)4.1% · Below median
Operating margin (12 months)4.0% · Below median
Growth and dividend
Revenue growth (quarter YoY)−0.8% · Below median
Balance sheet
Debt / equity1.90× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)70.2× · Priciest 25%
P/B6.28× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)2.87× · Pricier than median
Price / free cash flow43.3× · Priciest 25%
EV/EBITDA14.3× · Pricier than median
PEG1.29× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)0· sector 26
PAST (return on equity)39· sector 29
HEALTH (low debt)5· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Teva Pharma Industries Ltd (TEVA) overvalued or undervalued?
As of Nov 1, 2026, our model estimates a fair value of $20.82 versus a price of $42.09, about 51% lower (overvalued).
What is the fair value of TEVA?
Our model-based fair value for Teva Pharma Industries Ltd ADR is $20.82 (as of Nov 1, 2026), built from audited fundamentals. The current price: $42.09.
What is the quality score of TEVA?
Teva Pharma Industries Ltd ADR has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Teva Pharma Industries Ltd (TEVA)?
Our model-based price target is the fair value of $20.82 (as of Nov 1, 2026) from 22 valuation models. Cautious scenario $10.71, optimistic scenario $31.83. It is a calculation from audited fundamentals, not an analyst target.
What is the Teva Pharma Industries Ltd ADR stock forecast for 2026?
Our models put fair value at $20.82, about 51% lower versus a price of $42.09 (overvalued). Cautious scenario $10.71, optimistic scenario $31.83. The calculation is refreshed regularly with new filings.
What is the revenue of Teva Pharma Industries Ltd (TEVA)?
Teva Pharma Industries Ltd ADR reported trailing-twelve-month revenue of about $17.3B (latest available figure, as of Nov 1, 2026).
What growth is priced into Teva Pharma Industries Ltd (TEVA)?
For today's price to be fair in a discounted-cash-flow model, Teva Pharma Industries Ltd ADR would have to grow free cash flow by +25.9 % per year for five years (discount rate 8.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.7 % per year. As of Nov 1, 2026.
What discount rate (WACC) does the fair value of TEVA use?
Our models discount Teva Pharma Industries Ltd ADR at 8.8 %: a base by market capitalisation (large), damped by beta 0.82, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Teva Pharma Industries Ltd ADR that is +25.9 % per year a year over ten years, using the same discount rate (8.8 %) and the same formula as our fair value.
How much growth has Teva Pharma Industries Ltd (TEVA) delivered so far?
Over the past 5 years revenue at Teva Pharma Industries Ltd ADR grew +0.7 % a year. The price currently implies +25.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Teva Pharma Industries Ltd (TEVA) growing?
The median revenue growth in the sector is +6.4 % a year. That is the yardstick for the growth priced into Teva Pharma Industries Ltd ADR (+25.9 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Teva Pharma Industries Ltd (TEVA)?
The free-cash-flow yield on the price is 2.31 %: that much free cash flow Teva Pharma Industries Ltd ADR produces per unit of market value. When it exceeds the discount rate of our models (8.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Teva Pharma Industries Ltd (TEVA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Teva Pharma Industries Ltd ADR it is $20.82 per share (as of Nov 1, 2026), against a price of $42.09. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Teva Pharma Industries Ltd ADR stock overvalued or undervalued in 2026?
As of Nov 1, 2026, TEVA trades above its calculated fair value: price $42.09, fair value $20.82, a gap of about −51% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TEVA?
No. The price is what the market pays today ($42.09); the fair value is what the company's own numbers justify ($20.82). For Teva Pharma Industries Ltd ADR the two are $21.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Teva Pharma Industries Ltd ADR worth?
The market values Teva Pharma Industries Ltd ADR at about $49.7B (market capitalisation, as of Nov 1, 2026). Per share that is $42.09; our models calculate a fair value of $20.82 per share.
What do the bullish and bearish scenarios say about TEVA?
Our models span a range for Teva Pharma Industries Ltd ADR: cautious scenario $10.71, base $20.82, optimistic $31.83 per share (as of Nov 1, 2026, price $42.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TEVA?
Teva Pharma Industries Ltd ADR trades at a price-to-earnings ratio of 70.2 (as of Nov 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.82 is built from several models across several years. Other multiples: PEG 1.3, P/B 6.3, P/S 2.9, EV/EBITDA 14.3.
What is the PEG ratio of TEVA?
The PEG ratio of Teva Pharma Industries Ltd ADR is 1.29 (P/E divided by earnings growth, as of Nov 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Teva Pharma Industries Ltd (TEVA)?
Balance-sheet figures for Teva Pharma Industries Ltd ADR (as of Nov 1, 2026): return on equity 9.7%, debt of 1.90 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is TEVA from its 52-week high?
Teva Pharma Industries Ltd ADR trades at $42.09, at its 52-week high of $42.09 and 110% above the low of $20.03 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $20.82 is for.
Which stocks are comparable to Teva Pharma Industries Ltd ADR?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Jiangsu Hengrui Pharmaceuticals Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Teva Pharma Industries Ltd ADR stock attractive at the current price?
The data as of Nov 1, 2026: price $42.09, calculated fair value $20.82 (−51%), Quality Score 51/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TEVA calculated?
We run Teva Pharma Industries Ltd ADR through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $20.82, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Teva Pharma Industries Ltd ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Teva Pharma Industries Ltd (TEVA)?
The closing price on Oct 30, 2026 was $42.09. Our model-based fair value is $20.82, about 51% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Teva Pharma Industries Ltd ADR right now?
The price sits above even our optimistic bull case ($31.83). The favourable scenario is already priced in. The model range is unusually wide ($10.71 to $31.83). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Teva Pharma Industries Ltd ADR
How large is the market capitalisation of Teva Pharma Industries Ltd (TEVA)?
The market capitalisation of Teva Pharma Industries Ltd ADR is $49.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Teva Pharma Industries Ltd (TEVA)?
The price-to-sales ratio of Teva Pharma Industries Ltd ADR is 2.87 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Teva Pharma Industries Ltd (TEVA)?
Earnings per share at Teva Pharma Industries Ltd ADR are $0.6000 (price ÷ EPS = P/E 70.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Teva Pharma Industries Ltd (TEVA)?
The net margin of Teva Pharma Industries Ltd ADR is 4.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Teva Pharma Industries Ltd (TEVA)?
The return on equity (ROE) of Teva Pharma Industries Ltd ADR is 9.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Teva Pharma Industries Ltd (TEVA)?
On an EBIT basis the return on assets of Teva Pharma Industries Ltd ADR is 0.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Teva Pharma Industries Ltd (TEVA)?
The operating margin of Teva Pharma Industries Ltd ADR is 4.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Teva Pharma Industries Ltd (TEVA)?
Revenue at Teva Pharma Industries Ltd ADR is growing −0.8% versus a year earlier (3y avg +5.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Teva Pharma Industries Ltd (TEVA)?
Earnings per share at Teva Pharma Industries Ltd ADR are growing +72.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Teva Pharma Industries Ltd (TEVA) carry?
The net debt of Teva Pharma Industries Ltd ADR is $13.8B (fiscal year 2025, ≈ 12.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Teva Pharma Industries Ltd ADR in the live analysis
One click puts Teva Pharma Industries Ltd ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 1, 2026